SCHEMBL27233458

SCHEMBL27233458

CCOC(=O)COc1ccc(SCn2ncn(-c3ccc(Br)cc3)c2=O)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 3/20 0.42
PPARA Q07869 3/20 0.42
PPARG P37231 2/20 0.42
TBXAS1 P24557 1/20 0.40
GAA P10253 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HSD17B3 P37058 1/20 0.39
ADORA2A P29274 2/20 0.38
ADORA2B P29275 2/20 0.38
KDM4E B2RXH2 3/20 0.38
TP53 P04637 2/20 0.38
PTPN1 P18031 1/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
HSD17B10 Q99714 2/20 0.37
HPGD P15428 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27233511 0.89 PPARD (0.56) PPARDPPARAPPARG
SCHEMBL27233451 0.88 PPARD (0.47) PPARDPPARAPPARGNPSR1HSD17B3
SCHEMBL27233506 0.88 PPARD (0.43) PPARDPPARAPPARGGAAHSD17B3
SCHEMBL27233373 0.87 PPARD (0.43) PPARDPPARAPPARGNPSR1HSD17B3
SCHEMBL27233348 0.86 PPARD (0.43) PPARDPPARAPPARGGAAKDM4E
SCHEMBL27233381 0.86 ALDH1A1 (0.42) PPARDPPARAPPARGGAAKDM4E
SCHEMBL27233441 0.84 PPARD (0.49) PPARDPPARAPPARGKDM4ETP53
SCHEMBL30203049 0.83 PPARD (0.41) PPARDPPARAPPARGHSD17B3MAPT
SCHEMBL3575936 0.79 CYP2C19 (0.51) PPARDPPARAPPARGHSD17B3KDM4E
SCHEMBL27233400 0.78 PPARD (0.49) PPARDPPARAPPARGGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4378931-A1 TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF Harbin Medisan Pharmaceutical Co., LTD. (CN) 2024-06-05 EP claimed
US-20250188044-A1 TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION HARBIN MEDISAN PHARMACEUTICAL CO., LTD. (CN) 2025-06-12 US disclosed
EP-4378931-A1 TRIAZOLONE COMPOUND AND MEDICINAL USE THEREOF Harbin Medisan Pharmaceutical Co., LTD. (CN) 2024-06-05 EP disclosed
CN-114853686-B Triazolone compound and medical application thereof 中国药科大学 2023-06-20 CN disclosed
CN-114853686-A Triazole ketone compound and medical application thereof 中国药科大学 2022-08-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188044-A1 TRIAZOLONE COMPOUND, PHARMACEUTICAL USE THEREOF AND PHARMACEUTICAL COMPOSITION PPARD, PPARA, PPARG PPARD 1/4885PPARA 2/4885PPARG 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.